Diseases & Conditions
Grants & Contracts
News & Events
Provides services to facilitate preclinical development of materials that are derived from biotechnology processes. Services will be conducted at the appropriate regulatory compliance level dependent on the stage of product development.
The GCID use and develop or improve innovative applications of genomic technologies, such as RNA sequencing and metagenomics, and provide rapid and cost-efficient production of high-quality genome sequences of microorganisms, invertebrate vectors of infectious diseases, and hosts and host microbiomes. Multiple strains and isolates of specific microbial species, populations and communities have been and continue to be sequenced.
The In Vitro Assessment for Antimicrobial Activity program provides capability in a broad range of in vitro assessments to evaluate promising candidate countermeasures for antimicrobial activity against microbial pathogens and vectors, including those derived from clinical speci
Note: Devices are excluded.
The Phase I Clinical Trial Units for Therapeutics support the design, development, implementation, and conduct of Phase I clinical trials to assess safety, pharmacokinetics, and/or pharmacodynamics of licensed and investigational therapeutic products, including immunomodulatory agents and monoclo
This contract program supports the development and refinement of animal models and animal replacement technologies and provides in vivo preclinical testing services, ranging from screening and proof-of-concept to GLP efficacy studies.
The Structural Genomics Centers for Infectious Diseases provide the research community with: 3-D protein structures and protein-ligand complexes; Sequence-verified clones and peptides; Services that deliver requested 3-D structure determination; and Molecular screening of proteins in complex with inhibitors, cofactors and substrate analogs